Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Allergy Advocates New York Thanks Governor Hochul for Expanding Access and Affordability of Emergency Epinephrine in New York State

Allergy Advocates New York Logo, with text of Allergy Advocates NY. Single 2 line high Uppercase Italicized Blue A as the first character of Allergy Advocates. The balance of both words is in 2 lines of dark greay text. A White NY is is a slanted blue box at the end of the word Allergy. (PRNewsfoto/Allergy Advocates New York)

News provided by

Allergy Advocates New York

Dec 13, 2024, 12:29 ET

Share this article

Share toX

Share this article

Share toX

Three Bills Signed in the 2024 Legislative Season Greatly Expands Public Access to Epinephrine

ROCHESTER, N.Y., Dec. 13, 2024 /PRNewswire/ -- Many thanks to Governor Hochul for her leadership in recognizing the financial burden emergency epinephrine has on the two million New Yorkers managing life threatening allergies. Her signature on S.7114-A/A.6425-A caps the out-of-pocket costs at $100 per medically necessary medication, requiring insurers to cover the rest.

Continue Reading
Governor Hochul puts Money in Your Pockets
Governor Hochul puts Money in Your Pockets
Advocates in NYS Capital in Albany, May 14, 2024
Advocates in NYS Capital in Albany, May 14, 2024

"For people with severe allergies, immediate access to an Epi-Pen device can mean the difference between life and death," Governor Hochul said. "When every second counts, the last thing New Yorkers should have to worry about is whether they can afford the medication they need to survive an anaphylactic reaction. By signing this bill, we are putting people over profit and giving New Yorkers peace of mind by ensuring equitable access to this lifesaving emergency treatment."

While Allergy Advocates New York is grateful for the Governor's leadership, the Sponsors of the bill are also owed our gratitude. The primary Sponsors, NYS Senator Gustavo Rivera and Assemblymember Daniel O'Donnell are joined by many of their colleagues. In the Assembly we extend our thanks to AM Jen Lunsford, AM David Weprin, AM Amy Paulin, AM Linda Rosenthal, AM Charles Lavine, AM Jonathan Jacobson, and AM Anil Beephan among many others. On the Senate side we are grateful for the support of S. Cordell Clear, S. Jeremy Cooney, S. Andrew Gounardes, S. Pete Harckham, S. Robert Jackson, S. Lea Webb, and S. Timothy Kennedy.

The two million New Yorkers managing life threatening allergies are blessed to have a very active and effective group of advocates who we've had the honor of working with to advocate for life saving legislation to expand access to epinephrine, making all of us safer.

"On behalf of Greater Buffalo Food Allergy Alliance, Renata Doerr and I would like to thank Congressman Tim Kennedy for his support on the EpiPen Price Cap Act. We would also like to thank Governor Kathy Hochul for signing this important bill into law. This is a big win for all who need access to this life-saving medication. My son, Chase, is very excited to see how the advocacy work that he and so many others have been involved in is making a difference and is making this life-saving medication accessible for more individuals who need it. He said "This is so important for kids and adults who need to carry two EpiPens with them at all times!"
—Amy Burkett and Renata Doerr
Co-Founders, Greater Buffalo Food Allergy Alliance

"Thank you to NY for recognizing the importance of health equity. Implementing a price cap for epinephrine auto-injectors helps ensure families no longer have to decide between paying for the only antidote for anaphylaxis or their food and rent/mortgage."
—Stacey Saiontz
Westchester, NY

"Epinephrine is the first line drug for anaphylaxis. No one should ever have to choose between carrying this life saving medicine for their child or putting food on their table. Now, thanks to the tireless efforts of our legislators and grass roots advocates, they won't! "
– Jill Mindlin
Nassau County, NY

"As someone living with life threatening food allergies, I know how important it is to always have access to an epinephrine auto-injector. This legislation will ensure that everyone is able to have access to their life-saving medicine at all times. People's lives should not be put on the line because they cannot afford this life-saving medicine."
— Jared Saiontz
Westchester, NY

"For people like myself who live with food allergies, everyday has the potential to become a life or death situation and epinephrine is the only way to treat these serious reactions. Thanks to the hard work of so many advocates and the support from our legislators, cost will no longer be a barrier to anyone who needs access to this life saving medication."
— Maya Konoff
Nassau County, NY

I am happy to hear of the passing of S7114A. None of this would have been possible without the support of our community and outstanding state senator Sen.Oberacker who has been a champion for our cause . Being only 17 years old, I have seen the effects of price gouging and how detrimental it can be to family. Growing up with a single mother we often had to make major sacrifices for my health and medicine. This is a fantastic step forward for the food allergy community, New York has become a leader in disability and food allergy rights.
— Devin Sailer
Otsego County, NY

"Access to epinephrine is not just about convenience, it's about survival. For individuals managing food and non-food allergies, having an EpiPen on hand can mean the difference between life and death. Governor Hochul's leadership in capping costs ensures that lifesaving treatment is no longer out of reach for New Yorkers. This is a monumental step toward equity, safety, and peace of mind for all who navigate the challenges of severe allergies. Together, we're prioritizing lives over profit and ensuring everyone has access to the care they deserve."
—Thomas Silvera
Co-Founder & Vice President, Elijah-Alavi Foundation

"Today is a day to celebrate - thanks to the hard work and efforts of Assemblyman O'Donnell, Senator Rivera, Governor Hochul, and the entire state legislature, nearly two million New York food allergy families will now be better able to afford the only medicine that can save their lives during a food allergy reaction," said Sung Poblete, PhD, RN, CEO, FARE. "Today's bill signing sends a strong and clear message that food allergy families no longer have to worry about how they will afford their epinephrine - we are grateful to the leaders in Albany and our advocates statewide who helped make this law possible."  
— Sung Poblete, PhD, RN, CEO 
FARE 

With today's signing of legislation S.7114-A/A.6425-A, which requires insurers to cover medically necessary EpiPen devices and caps out-of-pocket costs, life-saving treatment has become more accessible and affordable for countless New Yorkers. A heartfelt thank you to Governor Kathy Hochul for her leadership, and to the bill sponsors, Senator Gustavo Rivera and Assemblymember Daniel J. O'Donnell, for championing this critical legislation. Thanks also to every passionate individual who worked tirelessly to make this monumental achievement possible.
—Georgina Cornago Cipriano
Founder, For Love of Giovanni Foundation

For the 2024 Legislative Session, in addition to S.7114-A/A.6425-A, we thank Governor Hochul for her leadership by signing into law two additional bills that further expand access to life saving epinephrine in an anaphylactic emergency.

S1078A/S2885A, Sponsored by Senator Andrew Goundardes and AssemblyMember Linda Rosenthal, requires places of public assembly to maintain epinephrine delivery devices and to have at least one employee who is trained in its use.

"This is the type of policy that seems so obvious, you can't believe it's not already law," said State Senator Andrew Gounardes. "Anaphylaxis can be terrifying and deadly. Requiring epinephrine devices to be easily accessible to New Yorkers at public venues is common sense, and ensures families don't have to live in fear every single time they go out to a show, a concert or a ballgame. I'm grateful to have worked alongside my constituent Lucia Zaremba, who approached me with this idea after an EpiPen saved her brother John's life. Thanks to her determination, we've passed a bill that can help millions of Americans live their lives more safely and securely." 

A07961/S07617, Sponsored by AM Rosenthal and Senator Julia Salazar. Is an amendment to Gio's Law expanding the population size of counties and towns permitted to stock and train all first responders in the use of epinephrine.

"Having a food allergy should not be a death sentence," said Assemblymember Linda B. Rosenthal. "However, New Yorkers suffering from allergies know that every single second, whether they're enjoying the ninth inning of a baseball game, the final act of a ballet or walking down the street, counts when they are experiencing an allergic reaction. Epinephrine is a lifesaving tool, but only when it is readily available.

"Many thanks to the amazing work and generosity of advocates across New York State desiring enhanced safety for their friends and family managing life threatening allergies. The leadership of Governor Hochul and the Legislative Sponsors of these three bills signed this session will have a tremendously positive impact for public safety of all New Yorkers with greatly expanded access to epinephrine, the only drug that stops an anaphylactic reaction."
 —Jon Terry and Toni Taylor, Co-Founders
Allergy Advocates New York

Rochester based Allergy Advocates New York represents over two million people across the state and is dedicated to expanding access to education and public access to epinephrine to ensure the safety of all New Yorkers from life threatening anaphylaxis reactions.

Media Contact
Toni Taylor
[email protected]
646-382-864

SOURCE Allergy Advocates New York

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

2 Million New Yorkers managing life threatening allergies need accurate food labeling and allergy prevention

2 Million New Yorkers managing life threatening allergies need accurate food labeling and allergy prevention

Allergy Advocates NY, along with Assembly Member Linda Rosenthal and Senator Andrew Gounardes, invite legislators to join a group of advocates and...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Federal and State Legislation

Federal and State Legislation

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.